Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus.

View through CrossRef
BACKGROUND: Barrett's oesophagus carries a 30-fold to 40-fold increased risk of oesophageal cancer. It is unknown whether endoscopic surveillance programmes reduce mortality from oesophageal cancer. METHODS: A cohort study was undertaken of all 166 patients in whom the diagnosis Barrett's oesophagus had been established between 1973 and 1986. RESULTS: One hundred and fifty five of 166 patients could be traced (93%). During a mean follow up of 9.3 years (amounting to 1440 patient years) eight patients had developed oesophageal cancer at random intervals (one case in 180 patient years). All but one of the tumours were diagnosed at endoscopy for symptoms, three in the stage of carcinoma in situ. Risk factors for the development of oesophageal cancer were extensive Barrett's oesophagus exceeding 10 cm (p = 0.02) and Barrett's ulcer at the time of intake (p = 0.009). Seventy six patients were alive; three had undergone surgery for oesophageal cancer and were without recurrence respectively, 12.8 years, 12.1 years, and 7 months postoperatively. Seventy nine patients had died; five of them had developed oesophageal cancer, but in only two cases this had been the cause of death (2.5%). CONCLUSIONS: Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. The patients of this cohort would not have benefited from an endoscopic surveillance programme.
Title: Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus.
Description:
BACKGROUND: Barrett's oesophagus carries a 30-fold to 40-fold increased risk of oesophageal cancer.
It is unknown whether endoscopic surveillance programmes reduce mortality from oesophageal cancer.
METHODS: A cohort study was undertaken of all 166 patients in whom the diagnosis Barrett's oesophagus had been established between 1973 and 1986.
RESULTS: One hundred and fifty five of 166 patients could be traced (93%).
During a mean follow up of 9.
3 years (amounting to 1440 patient years) eight patients had developed oesophageal cancer at random intervals (one case in 180 patient years).
All but one of the tumours were diagnosed at endoscopy for symptoms, three in the stage of carcinoma in situ.
Risk factors for the development of oesophageal cancer were extensive Barrett's oesophagus exceeding 10 cm (p = 0.
02) and Barrett's ulcer at the time of intake (p = 0.
009).
Seventy six patients were alive; three had undergone surgery for oesophageal cancer and were without recurrence respectively, 12.
8 years, 12.
1 years, and 7 months postoperatively.
Seventy nine patients had died; five of them had developed oesophageal cancer, but in only two cases this had been the cause of death (2.
5%).
CONCLUSIONS: Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus.
The patients of this cohort would not have benefited from an endoscopic surveillance programme.

Related Results

Upregulation of Twist in oesophageal squamous cell carcinoma is associated with neoplastic transformation and distant metastasis
Upregulation of Twist in oesophageal squamous cell carcinoma is associated with neoplastic transformation and distant metastasis
Background:The antiapoptotic and epithelial–mesenchymal transition activities of Twist have been implicated in the neoplastic transformation and the development of metastasis, resp...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract Introduction Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
391 P53 AS A UTILITY MARKER FOR RISK ASSESSMENT IN BARRETT’S OESOPHAGUS
391 P53 AS A UTILITY MARKER FOR RISK ASSESSMENT IN BARRETT’S OESOPHAGUS
Abstract   Staging and prognosis of a case of Barrett's oesophagus is done by identifying the presence and grade of dysplasia. H...
Comparison of Barrett and Kane keratoconic formulae in eyes with only posterior corneal changes
Comparison of Barrett and Kane keratoconic formulae in eyes with only posterior corneal changes
Abstract PURPOSE: The aim of this study was to compare the efficacy of Barrett Universal II (UII), Barrett total K, Barrett True-K keratoconus (K...

Back to Top